Biosplice Therapeutics, founded in 2008 and headquartered in San Diego, California, United States, has raised $778 million in total funding and reached a $12 billion valuation after its $120 million Series D round in 2021. The company develops RNA splicing–based therapeutics targeting diseases such as osteoarthritis, cancer, and neurological disorders. With 175 employees, Biosplice focuses on CLK/DYRK kinase modulation to restore normal cellular function, positioning itself as a global leader in RNA-based disease treatment and regenerative medicine.